Biological basis and clinical implications of acetylsalicylic acid resistance

Canadian Journal of Cardiology

Volumn 22, Issue 2, 2006, Pages 149-151

  Buchanan, Michael R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Acetylsalicylic acid; ASA; ASA resistance; Thrombotic risks

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; ACYLTRANSFERASE; ARACHIDONIC ACID; FIBRINOLYTIC AGENT; PROSTAGLANDIN SYNTHASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; FOLLOW UP; GRAFT FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; MEDICAL RESEARCH; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME; ACETYLATION; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY;

ACETYLATION; ACETYLTRANSFERASES; ARACHIDONIC ACID; ASPIRIN; CEREBROVASCULAR ACCIDENT; DRUG RESISTANCE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET ACTIVATING FACTOR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANE A2;

EID: 33645212853     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70255-0     Document Type: Article

References (16)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplateler therapy in various categories of patients. BMJ 1994;308:81-106. (Erratum in 1994;308:1540)
2. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
3. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM; BRAT Investigators. Results of the BRAT study - A pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16:1385-90.
4. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
5. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
6. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-32.
7. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S-64S.
8. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
9. Buchanan MR, Rischke JA, Hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res 1982;25:363-73.
10. Buchanan MR, Horsewood P, Brister SJ. Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13-HODE. Prostaglandins Leukot Essent Fatty Acids 1998;58:339-46.
11. Buchanan MR, Brister SJ. Individual variations in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
12. Wooltorton E. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ 2002;166:1692-3.
13. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
14. Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969;34:204-15.
15. Poston RS Jr, Gu J, White C, et al. Aspirin resistance provokes early graft failure in veins with poor endothelial integrity after off-pump coronary artery bypass. Proceedings of the 85th Annual Meeting of the American Association for Thoracic Surgery. San Francisco, April 10 to 13, 2005. (Abst)
16. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.